NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Atria Investments Inc bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the 4th quarter, HoldingsChannel.com reports. The fund bought 7,978 shares of the specialty ...

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...

NEW YORK, NY / ACCESS Newswire / March 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...

NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals ...

In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the other small cap pharma stocks. Emily Field, Head of European Pharma Research ...

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) stands against the ...

NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals ...

Supernus Pharmaceuticals, Inc., a biopharmaceutical company specializing in treatments for central nervous system diseases, announced that CEO Jack A. Khattar will engage in a fireside chat at the ...